Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy

INTRODUCTION: Mutations (MT) of the KRAS gene are the most common mutation in non-small cell lung cancer (NSCLC), seen in about 20–25% of all adenocarcinomas. Effect of KRAS MT on response to cytotoxic chemotherapy is unclear. METHODS: We undertook a single-institution retrospective analysis of 93 c...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Brady, Anna K., McNeill, Jonathan D., Judy, Brendan, Bauml, Joshua, Evans, Tracey L., Cohen, Roger B., Langer, Corey, Vachani, Anil, Aggarwal, Charu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2015
Konular:
Clinical Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4745798/
https://ncbi.nlm.nih.gov/pubmed/26471290
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller